The Mexican Ministry of Health recently completed a regulatory framework for registering biosimilar drugs and biotechnologies used in treating common chronic conditions like diabetes, arthritis, and hypertension. The regulation establishing the guidelines and requirements for approval takes effect this month. Requirements include manufacturing process controls, clinical trial procedures, and reference drug qualifications.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.